Edition:
India

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

4.80EUR
9:05pm IST
Change (% chg)

€0.20 (+4.35%)
Prev Close
€4.60
Open
€4.66
Day's High
€4.81
Day's Low
€4.55
Volume
73,297
Avg. Vol
172,843
52-wk High
€10.64
52-wk Low
€2.75

Select another date:

Fri, Jun 26 2020

BRIEF-Biocartis Group Says Idylla™ Allows Rapid and Accurate Mutation Testing Results

* US MULTICENTER STUDY SHOWS IDYLLA™ ALLOWS RAPID AND ACCURATE MUTATION TESTING RESULTS ACROSS DIFFERENT LABORATORY SETTINGS

BRIEF-Biocartis Creates New Share Option Plan

* ANNOUNCES TODAY THAT ITS BOARD OF DIRECTORS CREATED, WITHIN FRAMEWORK OF AUTHORIZED CAPITAL, 860,000 SHARE OPTIONS

BRIEF-Biocartis Suspends Guidance, Appoints New CFO

* BIOCARTIS' CASH POSITION END Q1 2020 AMOUNTED TO EUR 170.1M

BRIEF-Biocartis Announces Co-Commercialisation Agreement For SeptiCyte RAPID Test

* BIOCARTIS ANNOUNCES CO-COMMERCIALIZATION OF THE SEPTICYTE® RAPID TEST ON IDYLLA™ (CE-IVD) AND PROVIDES UPDATE ON COVID-19 IMPACT

BRIEF-Biocartis Creates New Share Option Plan

* REG-PRESS RELEASE BIOCARTIS GROUP NV: BIOCARTIS CREATES NEW SHARE OPTION PLAN & CANCELS OUTSTANDING POOL UNDER 2018 SHARE OPTION PLAN Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Biocartis: New Immuno-Oncology Project With Bristol-Myers Squibb

* BIOCARTIS ANNOUNCES NEW IMMUNO-ONCOLOGY PROJECT WITH BRISTOL-MYERS SQUIBB AIMED AT REGISTRATION OF IDYLLA™ MSI TEST IN CHINA

BRIEF-Rentokil Initial FY Revenue Rose 9.8%; CFO to retire

* RENTOKIL SAYS FY ONGOING REVENUE UP 8.6%, ORGANIC REVENUE UP 4.5%, ONGOING OPERATING PROFIT UP 10.5% AND FREE CASH FLOW CONVERSION OF 98.6%

Select another date: